Vimarsana
Biggest News Aggregation in the World

Page 22 - Itro News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Itro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Itro Today - Breaking & Trending Today

Vitro Architectural Glass Wins 2022 Design Award for Duquesne University Renovation - Vimarsana News

Vitro Architectural Glass Wins 2022 Design Award for Duquesne University Renovation

The UPMC Cooper Fieldhouse in Pittsburgh, Pa., has recently been recognized for its exceptional design featuring Solarban® R67 Starphire® glass from Vitro.

Nick Tanos joins Vitro Architectural Glass as a Commercial Account Manager - Vimarsana News

Nick Tanos joins Vitro Architectural Glass as a Commercial Account Manager

Vitro Architectural Glass announced that Nick Tanos has been appointed as a commercial account manager for Southern California, Southern Nevada, New Mexico and Arizona.

Join Vitro for four live Continuing Education webinars this February - Vimarsana News

Join Vitro for four live Continuing Education webinars this February

Earn AIA LU/HSW Credits with Vitro CE Webinars.

University of Arizona's HSIB Showcases Solarban® 90 Starphire® Glass - Vimarsana News

University of Arizona's HSIB Showcases Solarban® 90 Starphire® Glass

Featuring an impressive terracotta design for shading, Solarban® 90 Starphire® glass curtainwall, and expansive glazed windows, the HSIB is designed to be both aesthetically pleasing and high-performing.

NLS Pharmaceutics AG: NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity - Vimarsana News

NLS Pharmaceutics AG: NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity

The orexin deficit is believed to be the root cause of narcolepsyMazindol ER is the most advanced Orexin-2 partial receptor agonist in development for the treatment of narcolepsy and other rare sleep disordersMazindol